Loading
A phase 3 trial testing Telisotuzumab adizutecan in colorectal cancer, now recruiting.
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT07525206, led by AbbVie, and recruiting on the registry. Official title: An Open-Label, Randomised, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) Plus Bevacizumab to LONSURF (Trifluridine and Tipiracil) Plus Bevacizumab in Subjects With Refractory Metastatic Colorectal Cancer. Planned enrolment is 700 participants (estimated). The study started in 2026-05-22 and primary completion is expected in 2029-05. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan), Colorectal cancer.
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan), Colorectal cancer.
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan).
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan).
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan).
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan), Colorectal cancer.
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan).
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan), Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/